The anti-HIV-1 monoclonal antibodies 2F5 and 2G12 are well tolerated

By  

Inpharma, Vol. 1, Iss. 1327, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

What's in the Pipeline? Prospects for Monoclonal Antibodies (mAbs) as Therapies for Lung Diseases

By Li L.   Das A.M.   Torphy T.J.   Griswold D.E.  

Pulmonary Pharmacology & Therapeutics, Vol. 15, Iss. 5, 2002-10 ,pp. : 409-416

Academic Press

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Interleukin-2 as an Adjunct to Antiviral Therapy in HIV Infection

By Piscitelli S.C.  

Drug Safety, Vol. 22, Iss. 1, 2000-01 ,pp. : 19-31

Adis International

Access to resources Recommend Favorite

Role of Interleukin-2 in Patients with HIV Infection

By Pett Sarah L.   Kelleher Anthony D.   Emery Sean  

Drugs, Vol. 70, Iss. 9, 2010-06 ,pp. : 1115-1130

Adis International

Access to resources Recommend Favorite

Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection

By Re M.C.   Monari P.   Bon I.   Borderi M.   Chiodo F.   HIV-1 Emilia Romagna Infectious Disease Study Group  

International Journal of Antimicrobial Agents, Vol. 23, Iss. 2, 2004-02 ,pp. : 164-168

Elsevier

Access to resources Recommend Favorite